Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:02:14.057Z.
Calculation as of: 2026-10-06T15:02:14.057Z.
Quote observation: 2026-10-06T14:57:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d5e19f74cb926d0196b5f3ffb65db8ff8affa0edec331fa5277d4ca2ec73e8d
EARNINGS YIELD
N/A
Market Cap
$838118.00
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$870069.00
Earnings Yield
N/A
TTM Avg
30990441.81%
3Y Avg
30990441.81%
5Y Avg
30990441.81%
Market Cap
$1.04M
Earnings Yield
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.11M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | $829870.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838118.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $861994.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A | 30990441.81% | 30990441.81% | 30990441.81% |
| CDT Equity Inc. (CDT)vs › | $671998.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 0.00% | 0.00% | 0.00% |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $554487.00 | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute